{
  "symbol": "ADAG",
  "company_name": "Adagene Inc ADR",
  "ir_website": "https://www.adagene.com/investors",
  "structured_data": [
    {
      "section_name": "Investors & News",
      "links": [
        {
          "title": "Investors & News Homepage",
          "url": "https://investor.adagene.com/",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![logo](/sites/g/files/knoqqb57566/themes/site/nir_pid3859/dist/images/logo-adagene.png)](https://www.adagene.com/)\n\n  * [Overview](/)\n  * [Corporate](/corporate)\n    * [Corporate Profile](/corporate/corporate-profile)\n    * [Management](https://www.adagene.com/about/leadership-team/)\n    * [Board of Directors](https://www.adagene.com/about/board-of-directors/)\n    * [Key Advisors](https://www.adagene.com/about/key-advisors/)\n    * [Corporate Governance](/corporate/corporate-governance)\n  * [News & Events](/news-events)\n    * [News Releases](/news-events/news-releases)\n    * [Events](/news-events/events)\n    * [Presentations](/news-events/presentations)\n  * [Stock Information](/stock-information)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n    * [Historical Lookup](/stock-information/historical-lookup)\n    * [Investment Calculator](/stock-information/investment-calculator)\n    * [Analyst Coverage](/stock-information/analyst-coverage)\n  * [Financial Information](/financial-information)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [IR Resources](/ir-resources)\n    * [Investor FAQs](/ir-resources/investor-faqs)\n    * [Email Alerts](/ir-resources/email-alerts)\n    * [IR Contacts](/ir-resources/ir-contacts)\n\n\n\n# Investor Relations\n\n## Corporate Profile\n\nAdagene (NASDAQ: ADAG) is a publicly traded, global, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.\n\nOur platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by our immunotherapy pipeline. These features enable our novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. We have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology.\n\n![](sites/g/files/knoqqb57566/themes/site/nir_pid3859/dist/images/home-news.png)\n\n### Latest News\n\n[](/node/7931/pdf)\n\n2024.11.07 \n\n[Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting](/news-releases/news-release-details/adagene-presents-two-posters-new-insights-increased-therapeutic)\n\n[](/node/7926/pdf)\n\n2024.10.09 \n\n[Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting](/news-releases/news-release-details/adagene-announces-upcoming-poster-presentations-masked-anti-ctla)\n\n![](sites/g/files/knoqqb57566/themes/site/nir_pid3859/dist/images/home-events.png)\n\n### Events & Conferences\n\nMore events are coming soon. \n\n![](sites/g/files/knoqqb57566/themes/site/nir_pid3859/dist/images/home-feat.png)\n\n### Featured Items\n\n[2024 SITC Data Presentation](/static-files/acb35f42-efbf-48bc-8f14-8aa1d06b19f0)\n\n[Company Overview](/static-files/937a2d0f-58b4-4f2c-b2b3-16b8008255d7)\n\n[Pipeline Publications](https://www.adagene.com/pipeline/publications/)\n\n### Stock Quote\n\n  * Price\n\n  * Change\n\n  * Volume\n\n  * Yr High\n\n  * Yr Low\n\n\n\n\nMinimum 15 minutes delayed. Source: LSEG\n\n## Stock Chart\n\n  * [Today](#block-widgetstockchart)\n  * [3 mo.](#block-widgetstockchart-2)\n  * [6 mo.](#block-widgetstockchart-3)\n  * [1 yr.](#block-widgetstockchart-4)\n\n\n\n![](https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=ADAG.O-ADAG&scale=linear&duration=1dy&frequency=15min&gridLine=b&bgColor=ffffff&lineColor=0d6786&fillcolor=1db8b4|1db8b4&width=1000&height=400&bdr=2&volume=0&headerType=)\n\n![](https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=ADAG.O-ADAG&scale=linear&duration=3mo&frequency=1dy&gridLine=b&bgColor=ffffff&lineColor=0d6786&fillcolor=1db8b4|1db8b4&width=1000&height=400&bdr=2&volume=0&headerType=)\n\n![](https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=ADAG.O-ADAG&scale=linear&duration=6mo&frequency=1dy&gridLine=b&bgColor=ffffff&lineColor=0d6786&fillcolor=1db8b4|1db8b4&width=1000&height=400&bdr=2&volume=0&headerType=)\n\n![](https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=ADAG.O-ADAG&scale=linear&duration=1yr&frequency=1dy&gridLine=b&bgColor=ffffff&lineColor=0d6786&fillcolor=1db8b4|1db8b4&width=1000&height=400&bdr=2&volume=0&headerType=)\n"
        }
      ]
    }
  ]
}